Mary Mackle

723 total citations
22 papers, 463 citations indexed

About

Mary Mackle is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Mary Mackle has authored 22 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Psychiatry and Mental health, 5 papers in Pediatrics, Perinatology and Child Health and 4 papers in Pharmacology. Recurrent topics in Mary Mackle's work include Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (11 papers) and Electroconvulsive Therapy Studies (6 papers). Mary Mackle is often cited by papers focused on Schizophrenia research and treatment (13 papers), Bipolar Disorder and Treatment (11 papers) and Electroconvulsive Therapy Studies (6 papers). Mary Mackle collaborates with scholars based in United States, Netherlands and Japan. Mary Mackle's co-authors include Armin Szegedi, Jun Zhao, John Panagides, Maju Mathews, Pilar Cazorla, Ronald Landbloom, John M. Kane, Robert L. Findling, Joseph R. Calabrese and Suresh Durgam and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Mary Mackle

21 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Mackle United States 13 444 74 61 53 33 22 463
R.N. Marcus United States 5 396 0.9× 71 1.0× 59 1.0× 43 0.8× 38 1.2× 10 449
R. Marcus Germany 9 334 0.8× 52 0.7× 99 1.6× 81 1.5× 32 1.0× 26 387
Tawny L Bettinger United States 8 269 0.6× 69 0.9× 56 0.9× 42 0.8× 27 0.8× 13 369
Lara McCartney Australia 5 402 0.9× 48 0.6× 76 1.2× 31 0.6× 40 1.2× 5 495
Olubanke Olofinjana United Kingdom 7 195 0.4× 79 1.1× 47 0.8× 24 0.5× 13 0.4× 8 322
Mark D. Watanabe United States 7 252 0.6× 60 0.8× 84 1.4× 45 0.8× 33 1.0× 11 414
Baerbel Allingham United States 7 307 0.7× 27 0.4× 55 0.9× 57 1.1× 16 0.5× 10 365
Tram Tran-Johnson United States 8 237 0.5× 53 0.7× 143 2.3× 42 0.8× 28 0.8× 11 339
Rolando Gutierrez-Esteinou United States 8 385 0.9× 110 1.5× 45 0.7× 17 0.3× 61 1.8× 10 466
Nicolás David Ramírez Spain 11 206 0.5× 29 0.4× 60 1.0× 44 0.8× 23 0.7× 27 481

Countries citing papers authored by Mary Mackle

Since Specialization
Citations

This map shows the geographic impact of Mary Mackle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Mackle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Mackle more than expected).

Fields of papers citing papers by Mary Mackle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Mackle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Mackle. The network helps show where Mary Mackle may publish in the future.

Co-authorship network of co-authors of Mary Mackle

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Mackle. A scholar is included among the top collaborators of Mary Mackle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Mackle. Mary Mackle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mukai, Yuki, Robert Lupinacci, Stephen R. Marder, et al.. (2022). P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia. Biological Psychiatry. 91(9). S305–S305. 3 indexed citations
2.
Mukai, Yuki, et al.. (2022). Initial clinical profile of the PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia. Neuroscience Applied. 1. 100290–100290. 1 indexed citations
3.
Durgam, Suresh, et al.. (2017). Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study. Neuropsychiatric Disease and Treatment. Volume 13. 2021–2035. 8 indexed citations
4.
5.
Findling, Robert L., et al.. (2016). Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose Trial. Pediatric Drugs. 18(5). 367–378. 19 indexed citations
6.
7.
Findling, Robert L., Ronald Landbloom, Mary Mackle, et al.. (2015). Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia. Journal of Child and Adolescent Psychopharmacology. 25(5). 384–396. 32 indexed citations
8.
9.
Findling, Robert L., Armin Szegedi, Janelle M. Koppenhaver, et al.. (2015). Asenapine for the Acute Treatment of Pediatric Manic or Mixed Episode of Bipolar I Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 54(12). 1032–1041. 40 indexed citations
10.
Kemp, David E., Jun Zhao, Pilar Cazorla, et al.. (2013). Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder. The Journal of Clinical Psychiatry. 75(3). 238–245. 23 indexed citations
11.
Cazorla, Pilar, et al.. (2013). Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis. Neuropsychiatric Disease and Treatment. 9. 409–409. 13 indexed citations
12.
Mackle, Mary, et al.. (2013). Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatric Disease and Treatment. 9. 1145–1145. 23 indexed citations
13.
Szegedi, Armin, Paul E. Verweij, Wilbert van Duijnhoven, et al.. (2012). Meta-Analyses of the Efficacy of Asenapine for Acute Schizophrenia. The Journal of Clinical Psychiatry. 73(12). 1533–1540. 26 indexed citations
14.
15.
Szegedi, Armin, et al.. (2011). Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder. Journal of Clinical Psychopharmacology. 32(1). 46–55. 57 indexed citations
16.
Kane, John M., et al.. (2011). A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term Treatment. The Journal of Clinical Psychiatry. 72(3). 349–355. 69 indexed citations
17.
18.
Szegedi, Armin, Paul E. Verweij, Wilbert van Duijnhoven, et al.. (2011). Meta-analysis of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other atypical antipsychotics. European Psychiatry. 26(S2). 1511–1511. 1 indexed citations
19.
Cazorla, Pilar, et al.. (2011). P01-249-Weight change and metabolic effects of asenapine in placebo- or olanzapine-controlled studies. European Psychiatry. 26(S2). 250–250.
20.
Meltzer, Herbert Y., et al.. (2009). P.3.c.046 Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia. European Neuropsychopharmacology. 19. S536–S537. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R.N. Marcus Breakdown of academic impact, for papers by R. Marcus Breakdown of academic impact, for papers by Tawny L Bettinger Breakdown of academic impact, for papers by Lara McCartney Breakdown of academic impact, for papers by Olubanke Olofinjana Breakdown of academic impact, for papers by Mark D. Watanabe Breakdown of academic impact, for papers by Baerbel Allingham Breakdown of academic impact, for papers by Tram Tran-Johnson Breakdown of academic impact, for papers by Rolando Gutierrez-Esteinou Breakdown of academic impact, for papers by Nicolás David Ramírez
Rankless by CCL
2026